Quanterix 将来の成長
Future 基準チェック /06
Quanterixは、18.9%と9.9%でそれぞれ年率18.9%で利益と収益が成長すると予測される一方、EPSはgrowで35.2%年率。
主要情報
18.9%
収益成長率
35.18%
EPS成長率
| Life Sciences 収益成長 | 18.6% |
| 収益成長率 | 9.9% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 24 Aug 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Sep 09
QTRX: Lowered Expectations And Coverage Milestones Will Shape Future Alzheimer’s Test Upside
Analysts have lowered their price targets on Quanterix to $3 from $4, citing weaker Q2 results, a significant guidance cut, and ongoing commercial execution challenges in softer academic, government, and pharma end markets. Analyst Commentary Recent commentary on Quanterix points to a cautious stance from research desks.分析記事 • Aug 13
Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...Seeking Alpha • Aug 12
Quanterix: The Market Was Right To Lose Patience (Rating Downgrade)
Summary Quanterix (QTRX) is downgraded to Hold as its turnaround faces execution setbacks and delayed catalysts. Q2 revenue grew 34% but missed consensus, gross margins deteriorated and a $26.9M impairment raised even more concerns. Management cut 2026 revenue guidance and now expects cash flow breakeven in 2027, not 2026, undermining my prior bullish thesis. Commercial reorganization is underway, but meaningful improvement is deferred, increasing risk despite a lower valuation post-selloff. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 12
QTRX: Revised 2026 Guidance And Index Removal Will Support Stronger Earnings Power
Analysts have lowered their Quanterix price targets from about $4 to roughly $3, citing a weak Q2, a significant guidance cut, and ongoing challenges in end markets and commercial execution. What’s in the News for Quanterix Quanterix issued new guidance for the third quarter of 2026 and expects revenue to be flat to slightly above the second quarter level.ナラティブ更新 • Jul 08
QTRX: Recalibrated Expectations Will Shape Long Term Alzheimer’s Blood Test Upside
Analysts have trimmed their Quanterix price targets by a few dollars, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E. These factors collectively support a lower, but still supported, valuation range in the latest research.ナラティブ更新 • Jun 24
QTRX: Revised Models And 2026 Guidance Will Support Stronger Earnings Power
Analysts have reduced their Quanterix price targets by $3 to $4, citing updated fair value estimates, revised revenue growth expectations, and a lower future P/E assumption in their latest models. Analyst Commentary Recent commentary on Quanterix highlights that, even with lower price targets, some bullish analysts still see room for the stock to deliver on execution and growth expectations embedded in their updated models.
ナラティブ更新 • Jun 07
QTRX: Alzheimer’s Blood Test Progress Will Support Long-Term Upside Despite Recent Pessimism
Analysts have trimmed their Quanterix price targets by $3 to $4, citing updated views on the company that feed into slightly adjusted assumptions for discount rates, revenue growth, profit margins, and future P/E in the latest valuation work. Analyst Commentary Recent research updates reflect a more cautious tone around Quanterix, with bearish analysts trimming price targets by US$3 to US$4.ナラティブ更新 • May 24
QTRX: Alzheimer’s Blood Test Progress Will Underpin Long-Term Upside Despite Recent Caution
Analysts have reduced their price targets on Quanterix by $3 to $4, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E that point to a more measured outlook. Analyst Commentary Bearish analysts are reworking their fair value math on Quanterix, trimming price targets by US$3 to US$4 and signaling a more cautious stance on how the story could play out.ナラティブ更新 • May 01
QTRX: Alzheimer’s Blood Test Progress Will Support Long Term Upside Potential
Analysts have reduced their price target on Quanterix by $2, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that were reflected in recent Street research, including a $4 reduction highlighted by Canaccord. Analyst Commentary Recent research around the target cut focuses less on a single headline number and more on how updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E compare with execution risk.ナラティブ更新 • Apr 16
QTRX: Expanding Alzheimer’s Blood Screening Access Will Support Stronger Future Earnings Power
Narrative Update on Quanterix The latest analyst price target on Quanterix has been revised in line with updated assumptions for discount rate, revenue growth, profit margin, and future P/E, as analysts adjust their models to reflect a slightly different balance of growth expectations and risk. What's in the News Lucent Diagnostics partnered with Life Line Screening to offer a non-invasive blood based biomarker test for Alzheimer's disease nationally, with programs already underway in Florida, California, and Texas, using a mobile model that reaches community centers, churches, and senior centers (Client Announcements).ナラティブ更新 • Apr 02
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Analysts made a modest adjustment to their price target on Quanterix, trimming it by $0.10 to reflect slightly lower assumptions for revenue growth and profit margins, along with a somewhat higher expected future P/E and discount rate. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte, algorithmic blood test intended to aid in evaluating patients with cognitive symptoms for possible Alzheimer’s disease.ナラティブ更新 • Mar 19
QTRX: Alzheimer’s Blood Test Progress Will Support Stronger Earnings Power Ahead
Analysts have nudged their price target on Quanterix to $8.00 from $8.00, reflecting slightly updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, without a clear shift in overall valuation stance. What's in the News Quanterix issued earnings guidance for 2026, with expected revenues between US$169 million and US$174 million, providing a concrete management view of the top line for that year (Corporate guidance).ナラティブ更新 • Mar 04
QTRX: Alzheimer’s Blood Test Progress Will Shape Favorable Long Term Outlook
Analysts have made modest adjustments to their price targets on Quanterix, reflecting updated views on discount rates, revenue growth expectations, profit margins, and future P/E assumptions, while keeping their overall fair value estimate broadly in line with prior levels. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer's disease, supported by clinical evidence in over 1,800 symptomatic patients across three cohorts.ナラティブ更新 • Feb 18
QTRX: Alzheimer’s Blood Test Progress Will Drive Long-Term Upside Potential
Analysts have lifted their price target on Quanterix to $7.00 from $7.00, reflecting slight tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view essentially unchanged. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. FDA for a multi analyte algorithmic blood test for Alzheimer's disease, aiming to support evaluation of patients with cognitive symptoms using a non invasive, high performance diagnostic tool (Key Developments).ナラティブ更新 • Feb 04
QTRX: New Leadership And Neurodegenerative Pipeline Will Balance Near Term Multiple Risks
Narrative Update on Quanterix Analysts have lifted their fair value estimate for Quanterix from US$6.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that collectively support a higher long term price target range. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer’s disease, aimed at helping identify whether symptomatic patients are likely to have amyloid brain plaques using its Simoa technology and a panel of five biomarkers (p Tau 217, Ab42, Ab40, GFAP, NfL), supported by clinical evidence from more than 1,800 patients (Key Developments).ナラティブ更新 • Jan 21
QTRX: Future Leadership And Biomarker Data Will Shape Balanced 2025 Outlook
Analysts have raised their price target on Quanterix to 7.33 from 6.00 previously, reflecting updated fair value estimates based on adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News The board has appointed Everett Cunningham as Chief Executive Officer, effective January 19, 2026.分析記事 • Jan 10
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation's ( NASDAQ:QTRX ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a buy right now...ナラティブ更新 • Jan 07
QTRX: Multiple Sclerosis Biomarker Validation Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Quanterix to US$8.00 from US$7.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A study published in the journal Brain validates multiplexed Simoa assays for GFAP and NfL as a complementary approach for monitoring Multiple Sclerosis disease activity and progression.ナラティブ更新 • Dec 23
QTRX: Elevated Multiple And Higher Discount Rate Will Pressure Prospects
Analysts have raised their price target on Quanterix by approximately 20 percent to around 6 dollars per share, citing a modestly higher fair value estimate, slightly stronger long term profitability assumptions, and a willingness to apply a richer future earnings multiple, despite trimming revenue growth expectations and using a higher discount rate. What's in the News Publication of a landmark Brain journal study validating Quanterix Simoa assays for GFAP and NfL as a complementary, two biomarker approach for comprehensive Multiple Sclerosis disease monitoring, covering both acute inflammatory activity and slow progression (Key Developments) Evidence that elevated serum GFAP levels are significantly associated with higher risk of progression independent of relapse activity, highlighting a major unmet therapeutic need in MS and expanding the clinical utility of Quanterix assays (Key Developments) Creation of large Simoa-based normative reference databases for GFAP and NfL, incorporating age, sex, and BMI, alongside a free online interpretive tool to support more precise, individualized MS risk assessment (Key Developments) Updated 2025 revenue guidance of 130 million to 135 million dollars, implying pro forma revenue of 165 million to 170 million dollars for the year if combined operations are assumed, with an expected GAAP gross margin of 45 percent to 47 percent (Key Developments) Valuation Changes Fair Value Estimate has risen modestly from approximately 5 dollars to 6.0 dollars per share.分析記事 • Aug 28
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 29% Lower
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 29% after a relatively good period...ナラティブ更新 • Aug 15
Biomarker Diagnostics And Proteomics Will Shape Future Markets
Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.分析記事 • Aug 10
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...分析記事 • Jun 13
Even With A 33% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Those holding Quanterix Corporation ( NASDAQ:QTRX ) shares would be relieved that the share price has rebounded 33% in...分析記事 • Apr 08
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 30% Lower
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 30% in the last...
新しいナラティブ • Mar 28
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets.Seeking Alpha • Jan 11
Quanterix: Why Pursuing A Big Deal For Akoya?
Summary Quanterix's IPO in 2017 was highly speculative, with its Simoa technology promising ultra-sensitive diagnostics but accompanied by substantial operating losses and continued dilution. Despite revenue growth to $121 million in 2023, Quanterix still faces significant losses, and expects a $25-$30 million cash burn in 2024. Slower growth in 2024, compliance issues, and a controversial acquisition of Akoya Biosciences have pressured shares, raising concerns about combining two loss-making entities. The acquisition news led to a 20% share price drop, prompting a cautious outlook despite the potential synergies and growing revenue base. Read the full article on Seeking Alpha分析記事 • Nov 07
Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a really impressive month, gaining 36% after a shaky period...分析記事 • Oct 17
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 180 | -64 | -58 | -49 | 3 |
| 12/31/2027 | 158 | -70 | -52 | -43 | 3 |
| 12/31/2026 | 144 | -93 | -43 | -38 | 3 |
| 6/30/2026 | 153 | -123 | -82 | -81 | N/A |
| 3/31/2026 | 145 | -104 | -83 | -81 | N/A |
| 12/31/2025 | 139 | -107 | -80 | -77 | N/A |
| 9/30/2025 | 130 | -96 | -68 | -65 | N/A |
| 6/30/2025 | 126 | -70 | -33 | -30 | N/A |
| 3/31/2025 | 136 | -48 | -33 | -29 | N/A |
| 12/31/2024 | 137 | -39 | -39 | -35 | N/A |
| 9/30/2024 | 134 | -36 | -42 | -37 | N/A |
| 6/30/2024 | 129 | -34 | -40 | -35 | N/A |
| 3/31/2024 | 126 | -32 | -33 | -29 | N/A |
| 12/31/2023 | 122 | -28 | -23 | -19 | N/A |
| 9/30/2023 | 117 | -41 | -20 | -17 | N/A |
| 6/30/2023 | 112 | -70 | -34 | -28 | N/A |
| 3/31/2023 | 104 | -89 | -47 | -37 | N/A |
| 12/31/2022 | 106 | -100 | -60 | -49 | N/A |
| 9/30/2022 | 110 | -98 | -67 | -54 | N/A |
| 6/30/2022 | 111 | -79 | -66 | -54 | N/A |
| 3/31/2022 | 113 | -66 | -70 | -56 | N/A |
| 12/31/2021 | 111 | -56 | -61 | -48 | N/A |
| 9/30/2021 | 106 | -47 | -46 | -33 | N/A |
| 6/30/2021 | 110 | -30 | -37 | -27 | N/A |
| 3/31/2021 | 98 | -30 | -28 | -24 | N/A |
| 12/31/2020 | 86 | -32 | -27 | -23 | N/A |
| 9/30/2020 | 76 | -33 | -35 | -33 | N/A |
| 6/30/2020 | 60 | -45 | -36 | -34 | N/A |
| 3/31/2020 | 60 | -43 | N/A | -34 | N/A |
| 12/31/2019 | 57 | -41 | N/A | -26 | N/A |
| 9/30/2019 | 52 | -39 | N/A | -30 | N/A |
| 6/30/2019 | 47 | -37 | N/A | -28 | N/A |
| 3/31/2019 | 42 | -34 | N/A | -24 | N/A |
| 12/31/2018 | 38 | -32 | N/A | -29 | N/A |
| 9/30/2018 | 33 | -30 | N/A | -25 | N/A |
| 6/30/2018 | 28 | -30 | N/A | -26 | N/A |
| 3/31/2018 | 25 | -31 | N/A | -28 | N/A |
| 12/31/2017 | 23 | -31 | N/A | -22 | N/A |
| 9/30/2017 | 23 | -31 | N/A | -22 | N/A |
| 6/30/2017 | 21 | -30 | N/A | -20 | N/A |
| 3/31/2017 | 19 | -30 | N/A | -19 | N/A |
| 12/31/2016 | 18 | -28 | N/A | -18 | N/A |
| 12/31/2015 | 12 | -20 | N/A | -13 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: QTRX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: QTRXの収益 ( 9.9% ) US市場 ( 13.4% ) よりも低い成長が予測されています。
高い収益成長: QTRXの収益 ( 9.9% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: QTRXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/14 05:28 |
| 終値 | 2026/09/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Quanterix Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |